D-2570 in Moderate to Severe Plaque Psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, double-blind, placebo-controlled Phase II trial to evaluate the efficacy and safety of D-2570 tablets in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive D-2570 or placebo for a defined period, with ongoing safety monitoring and assessment of skin symptoms. The study uses standardized measures such as BODY SURFACE AREA, PASI, and PGA to determine response. Eligibility requires a confirmed diagnosis, stable disease activity for at least 6 months, and specific severity thresholds with normal laboratory results. The lead sponsor is InventisBio Co., Ltd, with study sites in Birmingham, AL; Phoenix, AZ; and Chula Vista, CA.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
* Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
* Within normal ranges of laboratory assessments

Exclusion Criteria:

* Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator

Where it's running

• Study Center
  Birmingham, Alabama, United States Recruiting
• Study Center
  Chula Vista, California, United States Recruiting
• Study Center
  San Antonio, Texas, United States Recruiting
• Study Center
  Phoenix, Arizona, United States Not yet recruiting
• Study Center
  Fountain Valley, California, United States Not yet recruiting
• Study Center
  Fremont, California, United States Not yet recruiting

Study contacts

• Study coordinator: Kathryn Stazzone
• Email: kathryn.stazzone@inventisbio.com
• Phone: 3025195966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

• SHR-1139 injectable treatment for adults with plaque psoriasis

  This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.

  Recruiting Phase 2 Guangdong Hengrui Pharmaceutical Co., Ltd · Guangzhou, Guangzhou · NCT07719530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.